AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04209933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate containing quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
Study NCT01848132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone: oral, 100 mg, days 1-5
Study NCT01848132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone: oral, 100 mg, days 1-5
Study NCT03733704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart rate variability analysis
Description: Heart rate variability analysis extracted from ECG during normal and obstructed breathing
Study NCT03927703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 12%
Description: Topically once daily
Study NCT03927703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topically once daily
Study NCT06481046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Description: Platelet Rich Plasma (PRP) prepared from patient blood, spun twice to concentrate platelets. 45 cc of initial blood resulting in 4cc of injectable PRP.
Study NCT03955211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 300 mg
Study NCT04209933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth capsules containing quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
Study NCT04209933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth particles A quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
Study NCT03955211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 400 mg
Study NCT03955211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock Applicator
Description: Applicator for instillation.
Study NCT03955211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg
Study NCT03955211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 975 mg to 1 g
Study NCT04613687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression bandage
Description: Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous
Study NCT03104686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short pasta (dry)
Description: 50g available carbohydrate of penne pasta
Study NCT03104686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long pasta (dry)
Description: 50g available carbohydrate of spaghetti pasta
Study NCT03104686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: 50g available carbohydrate of bread
Study NCT03104686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 50g available carbohydrate of glucose monohydrate
Study NCT01091116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN16132 - 0.125 mg
Description: Intra-articular administration of two low doses of MEN16132 at 2-week interval.
Study NCT01091116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN16132 - 0.25 mg
Description: Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
Study NCT04209933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth particles B quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 300 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
Study NCT01091116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN16132 - 0.5 mg
Description: Intra-articular injection of two high doses of MEN16132 at 2-week interval
Study NCT01091116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN16132 - 0.5 mg
Description: Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
Study NCT01091116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra-articular injection of 2 doses of Placebo control at 2-week interval
Study NCT02050256 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: continuing medical education and electronic decision support
Study NCT02820012 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scoliosis
Description: Questionnaires, radiography
Study NCT04437966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Chronic Disease Self-management program
Description: CDSMP workshops will last for approximately 2.5 hours and occur weekly for six weeks. Sessions will focus on appropriate diet for persons with hypertension and to facilitate weight loss; managing medications, adherence to medical clinic appointments; physical activity and stress management. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management program. Participants will also be given pill boxes and will be prompted by social media messages to make and keep clinic appointments as well as maintain a healthy lifestyle.
Study NCT02459028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology intervention
Description: Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks.
Study NCT02459028 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Psychology intervention (Control exercise)
Description: Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
Study NCT02897674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm olein
Description: two thirds of the 30% fat calories will come from palm olein
Study NCT02897674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Interesterified palm olein
Description: two thirds of the 30% fat calories will come from interesterified palm olein
Study NCT02897674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soybean oil
Description: two thirds of the 30% fat calories will come from soybean oil
Study NCT00433563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Once daily radiotherapy
Description: Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
Study NCT00433563 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Once daily radiotherapy
Description: Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
Study NCT02050256 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: education and electronic support
Description: Continuing medical education and electronic decision support to General Practitioners.
Study NCT02715115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
Study NCT02715115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry flavored solution and Water for Injection
Study NCT03852732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoNS Treatment
Description: PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages
Study NCT01949402 — intervention group
Intervention type: OTHER
Intervention: Computed Tomography
Description: The CT scan will be performed on a 16 slice GE Discovery 670 SPECT CT scanner. A slice thickness of 0.625mm will be used. Images are acquired during an inspiratory breath hold of up to 20 seconds to minimise movement artefact. The patient will be lying supine and the scan will be a non-contrast study. Using a low dose CT chest protocol (1.7 mSv) will minimise the exposure to ionising radiation of study participants.~Participants in the haemodialysis arm of the study will have a CT done before and after haemodialysis. Participants in all other arms will have a single CT scan done during their study visit.
Study NCT02058966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone
Description: Entacapone 200 mg oral dose
Study NCT02536222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case investigation of malaria passively detected cases with FT/FDA
Description: Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
Study NCT02757118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Crystalloid
Description: crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study NCT02058966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Methamphetamine 20 mg oral dose
Study NCT02058966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: capsules compounded to be of similar appearance to the active drugs
Study NCT02058966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules compounded to be of similar appearance to the active drugs
Study NCT02478736 — intervention group
Intervention type: OTHER
Intervention: No actual intervention
Description: Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
Study NCT02757118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous HES
Description: HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study NCT02846337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULTRAFILTRATION
Description: Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner.~Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance.~Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device.
Study NCT02846337 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ENHANCED MEDICAL TREATMENT
Description: * Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample~* Medical care adjustment in order to apply European and American guidance for chronic heart failure care~* Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed~* Physical rehabilitation suggestions by a physiologist~* Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance.
Study NCT00580827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo.
Study NCT00580827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: disulfiram at 62.5 mg/day for 12 weeks.
Study NCT00580827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram at 125 mg/day for 12 weeks.
Study NCT00580827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: disulfiram at 250 mg/day for 12 weeks.
Study NCT01634087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib administered orally
Study NCT01949402 — intervention group
Intervention type: OTHER
Intervention: Thoracic ultrasound
Description: The ultrasound will be performed by a single operator. The patient's position will ideally be with the patient sitting up at 45°. Ultrasound images and clips will be recorded at 10 points over each hemithorax - the 2nd, 4th and 6th intercostal spaces (ICS) in the mid-clavicular line; the 2nd, 4th and 6th ICS in the mid-axillary line; and the 2nd, 5th, 7th and 9th ICS posteriorly. Ultrasound estimation of the height of the right internal jugular vein will be undertaken. Central venous pressure will be calculated by adding 5cm. Inferior vena cava diameter will also be measured at end-inspiration and expiration. The time taken to perform each ultrasound will be recorded. Control, COPD and ILD groups will be scanned on a single occasion. Haemodialysis group will have 4 scans.
Study NCT01949402 — intervention group
Intervention type: OTHER
Intervention: Spirometry
Description: All participants in the study will undergo basic spirometry as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
Study NCT01949402 — intervention group
Intervention type: OTHER
Intervention: Blood tests
Description: All participants in the study will undergo blood tests as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
Study NCT03667638 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: Adding PRP to wound bed during surgical debridement
Study NCT03767660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
Study NCT02256423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REFERENCE 1: Nurofen® 200 mg tablet
Study NCT02256423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REFERENCE 2: Ibuprofen 200 mg soft gel capsule
Study NCT02256423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen 200 mg soft gel capsule
Study NCT02373449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RS-fMRI
Description: Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.
Study NCT02373449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
Study NCT03685344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine and Durvalumab
Description: intravenous infusion
Study NCT04170556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 160 mg/day 3 weeks on and 1 week off
Study NCT04170556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab at the dose of 1.5 mg/kg, 3 mg/kg or 240 mg/infusion every 2 weeks. Dose will be adjusted depending on the incidence of adverse events
Study NCT03161977 — intervention group
Intervention type: OTHER
Intervention: Mannitol
Description: Mannitol was intravenous infused within 15-20 mins when drilling skull
Study NCT03688633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Candesartan treatment with dose adjustments (8-16mg/day) during 6 months in accordance with adverse effects
Study NCT03688633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: patients will be followed as usual
Study NCT01407237 — intervention group
Intervention type: DRUG
Intervention: Angiotensin II Infusion
Description: Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
Study NCT06583161 — intervention group
Intervention type: BEHAVIORAL
Intervention: Moderate drinking
Description: Drink up to 16 grams of alcohol daily or almost daily \[repeated assessment center visit\] or 8-16 grams of alcohol 4 or more times per week \[web-based mental health questionnaire\]
Study NCT06583161 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quitting
Description: No alcohol consumption
Study NCT06583161 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social drinking
Description: Drink up to 16 grams of alcohol 1-2 days per week or drink 1-3 times per month or only on special occasions \[repeated assessment center visit\], or drink 8-16 grams of alcohol 2-3 times per week or drink 4 times per month or less \[web-based mental health questionnaire\]
Study NCT06583161 — intervention group
Intervention type: BEHAVIORAL
Intervention: Heavy/binge drinking
Description: Drink more than 16 grams of alcohol daily or almost daily or more than 40 grams of alcohol 1-2 days per week \[repeated assessment center visit\], or 24 grams of alcohol or more 4 or more times per week or 40 grams of alcohol or more 2-3 times per week \[web-based mental health questionnaire\]
Study NCT03897634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Microphone
Description: Experienced hearing aid users will be trained on and use a remote microphone for 30 days. Pre- and Post- measures will be taken to determine benefit. Participant characteristics will also be assessed (such as self-efficacy) to explore personality factors that may contribute to benefit from devices.
Study NCT02825771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Contacts Messages
Description: Text messages expressing care and support are sent following initial meeting on the following schedule: next day, 6 weekly, 9 bi-weekly, 7 monthly; one each on birthday, holiday, and seasonal (total of 25)
Study NCT02825771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care consists of services available to the participant in their community to reduce their suicide risk and improve their behavioral health
Study NCT02825771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care consists of services available to the participant in their community to reduce their suicide risk and improve their behavioral health
Study NCT00947115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples were collected at Years 5, 6, 7, 8, 9 and 10.
Study NCT00947115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervico-vaginal secretion (CVS) samples
Description: CVS samples were collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteered for this procedure.
Study NCT00724204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: follow on formula without probiotics
Description: A follow on formula without probiotics
Study NCT00724204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: follow on formula with Lactobacillus salivarius CECT5713
Description: follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day